Eli Lilly and Company
Treatment of primary biliary cholangitis and primary sclerosing cholangitis with baricitinib
Last updated:
Abstract:
Methods of treating Primary Biliary Cholangitis and/or Primary Sclerosing Cholangitis with baricitinib, including formulations and dose regimens. The amount of baricitinib may be administered as a 4 mg tablet or pill that includes one or more excipients. The amount of baricitinib may be administered daily or at some other frequency.
Status:
Grant
Type:
Utility
Filling date:
10 Oct 2019
Issue date:
14 Dec 2021